VOYXACT Preserves Kidney Function at Two Years in IgA Nephropathy

Company: Otsuka Pharmaceutical · Event Type: Phase III Data (24-Month, Detailed) · Product: VOYXACT (sibeprenlimab-szsi) · Indication: Primary IgA Nephropathy · Presentation: GlomCon, August 3, 2026 Summary Otsuka presented complete 24-month Phase III VISIONARY results showing a prespecified annualized eGFR slope of +0.3 mL/min/1.73 m²/year…